Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bryce Chackerian

Showing results (21-30 of 94) with videos related to

Pageof 10
Sort By:
Vaccine|September 3, 2021
A VLP-based vaccine targeting ANGPTL3 lowers plasma triglycerides in miceAlexandra Fowler, Maureen Sampson, Alan T Remaley, et al.
Pharmaceuticals (Basel, Switzerland)|August 28, 2021
RNA Phage VLP-Based Vaccine PlatformsDavid S Peabody, Julianne Peabody, Steven B Bradfute, et al.
Journal of Immunology (Baltimore, Md. : 1950)|November 22, 2002
Determinants of autoantibody induction by conjugated papillomavirus virus-like particlesBryce Chackerian, Petra Lenz, Douglas R Lowy, et al.
Biorxiv : the Preprint Server for Biology|April 22, 2024
Virus-like particle (VLP)-based vaccine targeting tau phosphorylated at Ser396/Ser404 (PHF1) site outperforms phosphorylated S199/S202 (AT8) site in reducing tau pathology and restoring cognitive deficits in the rTg4510 mouse model of tauopathyJonathan Hulse, Nicole Maphis, Julianne Peabody, et al.
Research Square|July 1, 2024
Virus-like particle (VLP)-based vaccine targeting tau phosphorylated at Ser396/Ser404 (PHF1) site outperforms phosphorylated S199/S202 (AT8) site in reducing tau pathology and restoring cognitive deficits in the rTg4510 mouse model of tauopathyJonathan Hulse, Nicole Maphis, Julianne Peabody, et al.
Plos One|October 31, 2015
Epitope-Specific Anti-hCG Vaccines on a Virus Like Particle PlatformJerri Caldeira, Jeremiah Bustos, Julianne Peabody, et al.
Journal of Molecular Biology|April 20, 2011
Peptide epitope identification by affinity selection on bacteriophage MS2 virus-like particlesBryce Chackerian, Jerri do Carmo Caldeira, Julianne Peabody, et al.
Plos One|November 28, 2012
VLPs displaying a single L2 epitope induce broadly cross-neutralizing antibodies against human papillomavirusEbenezer Tumban, Julianne Peabody, Mitchell Tyler, et al.
Expert Review of Vaccines|February 23, 2016
Progress and prospects for L2-based human papillomavirus vaccinesRosie T Jiang, Christina Schellenbacher, Bryce Chackerian, et al.
Viruses|April 26, 2025
Superior Potency of Synthetic Virus-like Structures in Vaccine-Induced Antibody Responses Compared to Qβ Bacteriophage Virus-like ParticlesAlexander R Meyer, Libo Li, Wei-Yun Wholey, et al.
Pageof 10

Showing results (21-30 of 94) with videos related to

Sort By:
Pageof 10
Vaccine|September 3, 2021
A VLP-based vaccine targeting ANGPTL3 lowers plasma triglycerides in miceAlexandra Fowler, Maureen Sampson, Alan T Remaley, et al.
Pharmaceuticals (Basel, Switzerland)|August 28, 2021
RNA Phage VLP-Based Vaccine PlatformsDavid S Peabody, Julianne Peabody, Steven B Bradfute, et al.
Journal of Immunology (Baltimore, Md. : 1950)|November 22, 2002
Determinants of autoantibody induction by conjugated papillomavirus virus-like particlesBryce Chackerian, Petra Lenz, Douglas R Lowy, et al.
Biorxiv : the Preprint Server for Biology|April 22, 2024
Virus-like particle (VLP)-based vaccine targeting tau phosphorylated at Ser396/Ser404 (PHF1) site outperforms phosphorylated S199/S202 (AT8) site in reducing tau pathology and restoring cognitive deficits in the rTg4510 mouse model of tauopathyJonathan Hulse, Nicole Maphis, Julianne Peabody, et al.
Research Square|July 1, 2024
Virus-like particle (VLP)-based vaccine targeting tau phosphorylated at Ser396/Ser404 (PHF1) site outperforms phosphorylated S199/S202 (AT8) site in reducing tau pathology and restoring cognitive deficits in the rTg4510 mouse model of tauopathyJonathan Hulse, Nicole Maphis, Julianne Peabody, et al.
Plos One|October 31, 2015
Epitope-Specific Anti-hCG Vaccines on a Virus Like Particle PlatformJerri Caldeira, Jeremiah Bustos, Julianne Peabody, et al.
Journal of Molecular Biology|April 20, 2011
Peptide epitope identification by affinity selection on bacteriophage MS2 virus-like particlesBryce Chackerian, Jerri do Carmo Caldeira, Julianne Peabody, et al.
Plos One|November 28, 2012
VLPs displaying a single L2 epitope induce broadly cross-neutralizing antibodies against human papillomavirusEbenezer Tumban, Julianne Peabody, Mitchell Tyler, et al.
Expert Review of Vaccines|February 23, 2016
Progress and prospects for L2-based human papillomavirus vaccinesRosie T Jiang, Christina Schellenbacher, Bryce Chackerian, et al.
Viruses|April 26, 2025
Superior Potency of Synthetic Virus-like Structures in Vaccine-Induced Antibody Responses Compared to Qβ Bacteriophage Virus-like ParticlesAlexander R Meyer, Libo Li, Wei-Yun Wholey, et al.
Pageof 10